Table 1.
Patient characteristics.
Table 2.
Serum antibody and co-expression status for MAGE antigens in ovarian cancer.
Figure 1.
A–I: Immunohistochemical staining for MAGE.
Specimens were stained with polyclonal antibody for MAGE-A3 (X20), clones 57b and A3 hybridoma supernatants for MAGE-A4 and MAGE-A10, respectively (x15). Specimens from the normal ovary and testis were used as negative and positive controls, respectively. A–C: Staining of the normal ovary showing no reactivity. D–F: Staining of the testis showing seminiferous tubules with strong intratubular staining, and absent non-specific reactivity. G–I: Staining of ovarian tumor demonstrating strong cytoplasmic and/or nuclear staining patterns.
Figure 2.
A–B: Co- expression of MAGE antigens in ovarian cancer.
(A) MAGE-A1 is co-expressed with –A3 or –A4 or –C1. MAGE-A3 is co-expressed with –A10. MAGE-A4 is co-expressed with MAGE-A10. The darker color intensity represents a stronger significance. The strongest associations are between MAGE-A1 to –A4, MAGE-A1 to –C1 and MAGE-A1 to –A3. Odds ratios (OR) greater than 1 imply the antigens tend to appear together. (B) Phylogenetic tree for MAGE expression. Each leaf ending in a pie chart symbolizes a person.
Figure 3.
Overall survival curves for patient groups based on MAGE-A10 and –C1 expression. MAGE-C1 expression predicts an improved progression free survival and a trend towards improved overall survival. Expression of MAGE-A10 dampens survival outcomes to the degree of patients with negative MAGE expression.
Table 3.
Patient Characteristics by MAGE Expression.
Figure 4.
Overall survival curves for patients groups based on the presence of anti-MAGE autoantibody. Humoral response to any MAGE antigen predicts poor overall survival, and no significant association with progression free survival.
Table 4.
Patient Characteristics by MAGE Serology.